Botulinum toxin and idiopathic dentoalveolar pain

Botulinum toxin

This review of the use of botulinum toxin (BONT-A) for pain-relief in patients with persistent idiopathic dentoalveolar pain included just 3 small uncontrolled studies providing a very limited amounh of very low quality evidence.

[read the full story...]

Stopping antidepressants: patient perspectives on barriers and facilitators

anastasia-dulgier-x2cooe_MaG8-unsplash

Timothy Nyugen and Dafni Katsampa summarise a qualitative review of patient perspectives on the barriers and facilitators to stopping antidepressants.

[read the full story...]

Mindfulness to support antidepressant withdrawal: patient views and experiences

dawid-zawila-zb2vBaHYB2I-unsplash

Hannah Bowers writes her debut blog on a recent qualitative study, which explores how mindfulness-based cognitive therapy can help people stop taking antidepressants and recover from depression. This paper includes the views and perspectives of participants in the 2015 PREVENT trial.

[read the full story...]

Cost-effectiveness of CBT for depression: uncertainty remains

micheile-henderson-ZVprbBmT8QA-unsplash

Chris Sampson reviews a recent US study which looks at the cost-effectiveness of CBT versus second-generation antidepressants for the initial treatment of major depressive disorder.

[read the full story...]

Are antidepressants safe? A new umbrella review of observational studies suggests they are, but we need more accurate data

shutterstock_1499989961

Andrea Cipriani and Anneka Tomlinson scrutinise a brand new umbrella review of the associations between antidepressants and adverse health outcomes, which suggests that antidepressants are safe for most people who experience mental health difficulties.

[read the full story...]

In adults with major depression, antidepressants may increase the risk of suicide

shutterstock_409500925

Douglas Badenoch explores a meta-analysis of follow-up data from clinical trials of antidepressants, which found a small but significant increase in suicide risk.

[read the full story...]

Intranasal esketamine for treatment-resistant depression: the first clinical study

shutterstock_174166007

Jodi Rintelman writes her debut elf blog on the first randomised controlled trial on the efficacy and safety of intranasal esketamine as an adjunctive treatment to antidepressants for treatment-resistant depression.

[read the full story...]

Medication for generalised anxiety disorder: new network meta-analysis

shutterstock_641208637

A group of UCL Masters Students summarise a recent network meta-analysis of drug treatment for generalised anxiety disorder, which finds that Venlafaxine, Pregabalin, Escitalopram and Duloxetine are all viable alternatives to Benzodiazepines.

[read the full story...]

Prescribing lithium for bipolar disorder: are we too scared?

Doctor writing prescription

Deenan Edward and Suhana Ahmed summarise a Scottish study of prescribing for bipolar disorder between 2009-2016, which identified a clear trend towards decreasing lithium use.

[read the full story...]

Higher doses of antidepressants “not optimal”, according to new review

shutterstock_322041725

Jonathon Tomlinson considers his options as a GP supporting people with depression and complex needs, after reading a new systematic review and dose-response meta-analysis, which suggests that higher doses of antidepressants bring maximum side effects with only marginal gains.

[read the full story...]